Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 6/2023

24.12.2022 | Retinal Disorders

Spontaneous remission of vision degrading myodesopsia of posterior vitreous detachment type

verfasst von: Xing Yang, Cheng Shi, Qiang Liu, Emmanuel Eric Pazo, Tiezhu Lin

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The study aims to observe the spontaneous remission of posterior vitreous detachment (PVD)-type vision degrading myodesopsia (VDM) during long-term follow-up.

Methods

We retrospectively reviewed VDM patients with PVD type that refused any treatment. The ratio and time of significant spontaneous remission of floater symptoms occurring were described. The associated factors with significant remission of floater symptoms were analyzed in the univariate and multivariate logistic regression analyses.

Results

In total, 179 patients with VDM were assessed. The mean age of all patients was 60.56 ± 0.47 years old, and the mean duration of follow-up was 23.89 ± 6.63 months. Of the patients, 40.78% have significant improvement in their floater symptoms after mean 16.55 ± 10.63-month follow-up. Myopia (OR = 0.280, 95% CI = 0.084–0.932, P = 0.038), the number of floaters > 3 (OR = 0.343, 95% CI = 0.172–0.683, P = 0.002), and floaters with string-like pattern (OR = 0.370, 95% CI = 0.166–0.824, P = 0.015) and blocky pattern (OR = 0.299, 95% CI = 0.090–0.993, P = 0.049) were negatively correlated with the significant spontaneous remission of VDM symptoms in the multiple binary logistic regression analysis.

Conclusions

Approximately 40% of VDM patients with PVD may experience significant spontaneous remission during long-term follow-up. Patients that are non-myopic and with fewer floaters are more likely to feel relief from VDM symptoms. Floaters with string-like or blocky patterns are less likely to undergo spontaneous remission.
Literatur
1.
Zurück zum Zitat Webb BF, Webb JR, Schroeder MC et al (2013) Prevalence of vitreous floaters in a community sample of smartphone users. Int J Ophthalmol 6:402–405PubMedPubMedCentral Webb BF, Webb JR, Schroeder MC et al (2013) Prevalence of vitreous floaters in a community sample of smartphone users. Int J Ophthalmol 6:402–405PubMedPubMedCentral
2.
Zurück zum Zitat Milston R, Madigan MC, Sebag J (2016) Vitreous floaters: etiology, diagnostics, and management. Surv Ophthalmol 61:211–227CrossRefPubMed Milston R, Madigan MC, Sebag J (2016) Vitreous floaters: etiology, diagnostics, and management. Surv Ophthalmol 61:211–227CrossRefPubMed
3.
Zurück zum Zitat Broadhead GK, Hong T, Chang AA (2020) To treat or not to treat: management options for symptomatic vitreous floaters. Asia Pac J Ophthalmol (Phila) 9:96–103CrossRefPubMed Broadhead GK, Hong T, Chang AA (2020) To treat or not to treat: management options for symptomatic vitreous floaters. Asia Pac J Ophthalmol (Phila) 9:96–103CrossRefPubMed
4.
Zurück zum Zitat Shah CP, Heier JS (2017) YAG laser vitreolysis vs sham YAG vitreolysis for symptomatic vitreous floaters: a randomized clinical trial. JAMA Ophthalmol 135:918–923CrossRefPubMedPubMedCentral Shah CP, Heier JS (2017) YAG laser vitreolysis vs sham YAG vitreolysis for symptomatic vitreous floaters: a randomized clinical trial. JAMA Ophthalmol 135:918–923CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Ludwig GD, Gemelli H, Nunes GM et al (2021) Efficacy and safety of Nd:YAG laser vitreolysis for symptomatic vitreous floaters: a randomized controlled trial. Eur J Ophthalmol 31:909–914CrossRefPubMed Ludwig GD, Gemelli H, Nunes GM et al (2021) Efficacy and safety of Nd:YAG laser vitreolysis for symptomatic vitreous floaters: a randomized controlled trial. Eur J Ophthalmol 31:909–914CrossRefPubMed
6.
Zurück zum Zitat Lin T, Li T, Zhang X et al (2022) The efficacy and safety of YAG laser vitreolysis for symptomatic vitreous floaters of complete PVD or non-PVD. Ophthalmol Ther 11:201–214CrossRefPubMed Lin T, Li T, Zhang X et al (2022) The efficacy and safety of YAG laser vitreolysis for symptomatic vitreous floaters of complete PVD or non-PVD. Ophthalmol Ther 11:201–214CrossRefPubMed
7.
Zurück zum Zitat Souza CE, Lima LH, Nascimento H et al (2020) Objective assessment of YAG laser vitreolysis in patients with symptomatic vitreous floaters. Int J Retina Vitreous 21(6):1CrossRef Souza CE, Lima LH, Nascimento H et al (2020) Objective assessment of YAG laser vitreolysis in patients with symptomatic vitreous floaters. Int J Retina Vitreous 21(6):1CrossRef
8.
Zurück zum Zitat García BG, Orduna Magán C, Alvarez-Peregrina C et al (2020) Nd:YAG laser vitreolysis and health-related quality of life in patients with symptomatic vitreous floaters. Eur J Ophthalmol 7:11206721211008036 García BG, Orduna Magán C, Alvarez-Peregrina C et al (2020) Nd:YAG laser vitreolysis and health-related quality of life in patients with symptomatic vitreous floaters. Eur J Ophthalmol 7:11206721211008036
9.
Zurück zum Zitat Ryan EH (2021) Current treatment strategies for symptomatic vitreous opacities. Curr Opin Ophthalmol 32:198–202CrossRefPubMed Ryan EH (2021) Current treatment strategies for symptomatic vitreous opacities. Curr Opin Ophthalmol 32:198–202CrossRefPubMed
10.
Zurück zum Zitat Schulz-Key S, Carlsson JO, Crafoord S (2011) Longterm follow-up of pars plana vitrectomy for vitreous floaters: complications, outcomes and patient satisfaction. Acta Ophthalmol 89:159–165CrossRefPubMed Schulz-Key S, Carlsson JO, Crafoord S (2011) Longterm follow-up of pars plana vitrectomy for vitreous floaters: complications, outcomes and patient satisfaction. Acta Ophthalmol 89:159–165CrossRefPubMed
11.
Zurück zum Zitat Shah CP, Fine HF (2018) Management of floaters. Ophthalmic Surg Lasers Imaging Retina 49:388–391CrossRefPubMed Shah CP, Fine HF (2018) Management of floaters. Ophthalmic Surg Lasers Imaging Retina 49:388–391CrossRefPubMed
12.
Zurück zum Zitat Wang MD, Truong C, Mammo Z et al (2021) Swept source optical coherence tomography compared to ultrasound and biomicroscopy for diagnosis of posterior vitreous detachment. Clin Ophthalmol 15:507–512CrossRefPubMedPubMedCentral Wang MD, Truong C, Mammo Z et al (2021) Swept source optical coherence tomography compared to ultrasound and biomicroscopy for diagnosis of posterior vitreous detachment. Clin Ophthalmol 15:507–512CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Tassignon MJ, Ní Dhubhghaill S, Ruiz Hidalgo I et al (2016) Subjective grading of subclinical vitreous floaters. Asia Pac J Ophthalmol (Phila) 5(2):104–109CrossRefPubMed Tassignon MJ, Ní Dhubhghaill S, Ruiz Hidalgo I et al (2016) Subjective grading of subclinical vitreous floaters. Asia Pac J Ophthalmol (Phila) 5(2):104–109CrossRefPubMed
14.
Zurück zum Zitat van Overdam KA, Bettink-Remeijer MW, Klaver CC et al (2005) Symptoms and findings predictive for the development of new retinal breaks. Arch Ophthalmol 123(4):479–484CrossRefPubMed van Overdam KA, Bettink-Remeijer MW, Klaver CC et al (2005) Symptoms and findings predictive for the development of new retinal breaks. Arch Ophthalmol 123(4):479–484CrossRefPubMed
15.
Zurück zum Zitat Delaney YM, Oyinloye A, Benjamin L (2002) Nd:YAG vitreolysis and pars plana vitrectomy: surgical treatment for vitreous floaters. Eye (Lond) 16:21–26CrossRefPubMed Delaney YM, Oyinloye A, Benjamin L (2002) Nd:YAG vitreolysis and pars plana vitrectomy: surgical treatment for vitreous floaters. Eye (Lond) 16:21–26CrossRefPubMed
16.
Zurück zum Zitat Chuo JY, Lee TY, Hollands H et al (2006) Risk factors for posterior vitreous detachment: a case-control study. Am J Ophthalmol 142:931–937CrossRefPubMed Chuo JY, Lee TY, Hollands H et al (2006) Risk factors for posterior vitreous detachment: a case-control study. Am J Ophthalmol 142:931–937CrossRefPubMed
17.
Zurück zum Zitat Smith TJ (1984) Dexamethasone regulation of glycosaminoglycan synthesis in cultured human skin fibroblasts. Similar effects of glucocorticoid and thyroid hormones. J Clin Invest 74:2157–2163CrossRefPubMedPubMedCentral Smith TJ (1984) Dexamethasone regulation of glycosaminoglycan synthesis in cultured human skin fibroblasts. Similar effects of glucocorticoid and thyroid hormones. J Clin Invest 74:2157–2163CrossRefPubMedPubMedCentral
18.
20.
Zurück zum Zitat Su D, Shah CP, Hsu J (2020) Laser vitreolysis for symptomatic floaters is not yet ready for widespread adoption. Surv Ophthalmol 65:589–591CrossRefPubMed Su D, Shah CP, Hsu J (2020) Laser vitreolysis for symptomatic floaters is not yet ready for widespread adoption. Surv Ophthalmol 65:589–591CrossRefPubMed
21.
Zurück zum Zitat Katsanos A, Tsaldari N, Gorgoli K et al (2020) Safety and efficacy of YAG laser vitreolysis for the treatment of vitreous floaters: an overview. Adv Ther 37:1319–1327CrossRefPubMedPubMedCentral Katsanos A, Tsaldari N, Gorgoli K et al (2020) Safety and efficacy of YAG laser vitreolysis for the treatment of vitreous floaters: an overview. Adv Ther 37:1319–1327CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Singh IP (2020) Modern vitreolysis-YAG laser treatment now a real solution for the treatment of symptomatic floaters. Surv Ophthalmol 65:581–588CrossRefPubMed Singh IP (2020) Modern vitreolysis-YAG laser treatment now a real solution for the treatment of symptomatic floaters. Surv Ophthalmol 65:581–588CrossRefPubMed
23.
Zurück zum Zitat Ivanova T, Jalil A, Antoniou Y et al (2016) Vitrectomy for primary symptomatic vitreous opacities: an evidence-based review. Eye (Lond) 30:645–655CrossRefPubMed Ivanova T, Jalil A, Antoniou Y et al (2016) Vitrectomy for primary symptomatic vitreous opacities: an evidence-based review. Eye (Lond) 30:645–655CrossRefPubMed
24.
Zurück zum Zitat Nguyen JH, Nguyen-Cuu J, Yu F et al (2019) Assessment of vitreous structure and visual function after neodymium:yttrium-aluminum-garnet laser vitreolysis. Ophthalmology 126:1517–1526CrossRefPubMed Nguyen JH, Nguyen-Cuu J, Yu F et al (2019) Assessment of vitreous structure and visual function after neodymium:yttrium-aluminum-garnet laser vitreolysis. Ophthalmology 126:1517–1526CrossRefPubMed
25.
Zurück zum Zitat Shah CP, Heier JS (2020) Long-term follow-up of efficacy and safety of YAG vitreolysis for symptomatic weiss ring floaters. Ophthalmic Surg Lasers Imaging Retina 51:85–88CrossRefPubMed Shah CP, Heier JS (2020) Long-term follow-up of efficacy and safety of YAG vitreolysis for symptomatic weiss ring floaters. Ophthalmic Surg Lasers Imaging Retina 51:85–88CrossRefPubMed
27.
Zurück zum Zitat de Nie KF, Crama N, Tilanus MA et al (2013) Pars plana vitrectomy for disturbing primary vitreous floaters: clinical outcome and patient satisfaction. Graefes Arch Clin Exp Ophthalmol 251:1373–1382CrossRefPubMed de Nie KF, Crama N, Tilanus MA et al (2013) Pars plana vitrectomy for disturbing primary vitreous floaters: clinical outcome and patient satisfaction. Graefes Arch Clin Exp Ophthalmol 251:1373–1382CrossRefPubMed
28.
Zurück zum Zitat Mason JO 3rd, Neimkin MG, Mason JO 4th et al (2014) Safety, efficacy, and quality of life following sutureless vitrectomy for symptomatic vitreous floaters. Retina 34:1055–1061CrossRefPubMed Mason JO 3rd, Neimkin MG, Mason JO 4th et al (2014) Safety, efficacy, and quality of life following sutureless vitrectomy for symptomatic vitreous floaters. Retina 34:1055–1061CrossRefPubMed
29.
Zurück zum Zitat Lin Z, Zhang R, Liang QH et al (2017) Surgical outcomes of 27-gauge pars plana vitrectomy for symptomatic vitreous floaters. J Ophthalmol 2017:5496298CrossRefPubMedPubMedCentral Lin Z, Zhang R, Liang QH et al (2017) Surgical outcomes of 27-gauge pars plana vitrectomy for symptomatic vitreous floaters. J Ophthalmol 2017:5496298CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Sommerville DN (2015) Vitrectomy for vitreous floaters: analysis of the benefits and risks. Curr Opin Ophthalmol 26:173–176CrossRefPubMed Sommerville DN (2015) Vitrectomy for vitreous floaters: analysis of the benefits and risks. Curr Opin Ophthalmol 26:173–176CrossRefPubMed
31.
32.
Zurück zum Zitat Rubino SM, Parke DW 3rd, Lum F (2021) Return to the operating room after vitrectomy for vitreous opacities: intelligent research in sight registry analysis. Ophthalmol Retina 5:4–8CrossRefPubMed Rubino SM, Parke DW 3rd, Lum F (2021) Return to the operating room after vitrectomy for vitreous opacities: intelligent research in sight registry analysis. Ophthalmol Retina 5:4–8CrossRefPubMed
33.
Zurück zum Zitat Serpetopoulos CN, Korakitis RA (1998) An optical explanation of the entoptic phenomenon of ‘clouds’ in posterior vitreous detachment. Ophthalmic Physiol Opt 18:446–451CrossRefPubMed Serpetopoulos CN, Korakitis RA (1998) An optical explanation of the entoptic phenomenon of ‘clouds’ in posterior vitreous detachment. Ophthalmic Physiol Opt 18:446–451CrossRefPubMed
34.
Zurück zum Zitat Kalavar M, Hubschman S, Hudson J et al (2021) Evaluation of available online information regarding treatment for vitreous floaters. Semin Ophthalmol 36:58–63CrossRefPubMedPubMedCentral Kalavar M, Hubschman S, Hudson J et al (2021) Evaluation of available online information regarding treatment for vitreous floaters. Semin Ophthalmol 36:58–63CrossRefPubMedPubMedCentral
35.
36.
Zurück zum Zitat Gishti O, van den Nieuwenhof R, Verhoekx J et al (2019) Symptoms related to posterior vitreous detachment and the risk of developing retinal tears: a systematic review. Acta Ophthalmol 97:347–352CrossRefPubMed Gishti O, van den Nieuwenhof R, Verhoekx J et al (2019) Symptoms related to posterior vitreous detachment and the risk of developing retinal tears: a systematic review. Acta Ophthalmol 97:347–352CrossRefPubMed
37.
Zurück zum Zitat van Overdam KA, Bettink-Remeijer MW, Mulder PG et al (2001) Symptoms predictive for the later development of retinal breaks. Arch Ophthalmol 119:1483–1486CrossRefPubMed van Overdam KA, Bettink-Remeijer MW, Mulder PG et al (2001) Symptoms predictive for the later development of retinal breaks. Arch Ophthalmol 119:1483–1486CrossRefPubMed
Metadaten
Titel
Spontaneous remission of vision degrading myodesopsia of posterior vitreous detachment type
verfasst von
Xing Yang
Cheng Shi
Qiang Liu
Emmanuel Eric Pazo
Tiezhu Lin
Publikationsdatum
24.12.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 6/2023
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-022-05948-4

Weitere Artikel der Ausgabe 6/2023

Graefe's Archive for Clinical and Experimental Ophthalmology 6/2023 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

CME: Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Wird ein Glaukom chirurgisch behandelt, ist die anschließende Wundheilung von entscheidender Bedeutung. In diesem CME-Kurs lernen Sie, welche Pathomechanismen der Vernarbung zugrunde liegen, wie perioperativ therapiert und Operationsversagen frühzeitig erkannt werden kann.

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.